about
sameAs
Activity of the streptogramin antibiotic etamycin against methicillin-resistant Staphylococcus aureusDifferences in the Enterococcus faecalis lsa locus that influence susceptibility to quinupristin-dalfopristin and clindamycinAntibiotic sensitivity profiles determined with an Escherichia coli gene knockout collection: generating an antibiotic bar code.Group B streptococcal disease in nonpregnant patients: emergence of highly resistant strains of serotype Ib in Taiwan in 2006 to 2008.An Enterococcus faecalis ABC homologue (Lsa) is required for the resistance of this species to clindamycin and quinupristin-dalfopristinMacrocyclic drugs and synthetic methodologies toward macrocyclesTreatment of bacterial skin and skin structure infections.Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria.Tigecycline for the treatment of infections due to resistant Gram-positive organisms.Investigational treatments for postoperative surgical site infections.Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.Prospects for new antibiotics: a molecule-centered perspective.Antibiotic resistance in Staphylococcus aureus. Current status and future prospects.Staphylococcus aureus mutants isolated via exposure to nonfluorinated quinolones: detection of known and unique mutations.Changes in the prevalence of vancomycin-resistant enterococci in response to antimicrobial formulary interventions: impact of progressive restrictions on use of vancomycin and third-generation cephalosporins.
P2860
Q29013706-4843244A-CA57-43EA-B05C-525E773A8C37Q33555837-D6931975-97D9-4CC5-A8C7-1CF7F8D7A93BQ33768891-9A12C03C-DA65-4F27-B314-C62C7669ADFFQ33963491-05962BFA-EA3D-41CB-BEA2-5E58F3AC92A9Q34109292-7281E500-3410-4BAF-860A-28A0851CB899Q34740721-B371D22F-8566-4395-8027-24FEA899BBC6Q35183731-71D39AE0-E084-45B5-ABE9-166ED1AE8AD0Q35637071-87C314C5-9CA4-4B82-8CF3-6B833518C2B2Q36376443-CF6E1BB2-491B-4648-B6F9-3DE9AFEEA41EQ36715742-320792CB-7DBF-4302-B6AB-13BAB6E07DE3Q36718474-C3ED90DF-795C-4557-A9AC-A9A2355B7667Q38113689-D3F5ABAC-65C0-4439-B1DF-C47DCF75B0FAQ38728885-DF787F4E-1044-4376-B596-FFC51AD3E112Q39479108-6CDD7CD4-26A6-4D95-923F-C1C9D5485CD9Q40606947-35925D32-1132-4D03-AAF2-E0ECB5500702
P2860
description
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2001
@ast
im Jahr 2001 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: 2001)
@en
vedecký článok (publikovaný 2001-01)
@sk
vědecký článek publikovaný v roce 2001
@cs
wetenschappelijk artikel (gepubliceerd in 2001-01)
@nl
наукова стаття, опублікована в січні 2001
@uk
مقالة علمية (نشرت عام 2001)
@ar
name
Quinupristin/dalfopristin: a therapeutic review
@ast
Quinupristin/dalfopristin: a therapeutic review
@en
Quinupristin/dalfopristin: a therapeutic review
@nl
type
label
Quinupristin/dalfopristin: a therapeutic review
@ast
Quinupristin/dalfopristin: a therapeutic review
@en
Quinupristin/dalfopristin: a therapeutic review
@nl
prefLabel
Quinupristin/dalfopristin: a therapeutic review
@ast
Quinupristin/dalfopristin: a therapeutic review
@en
Quinupristin/dalfopristin: a therapeutic review
@nl
P1476
Quinupristin/dalfopristin: a therapeutic review
@en
P2093
D R Allington
P356
10.1016/S0149-2918(01)80028-X
P407
P577
2001-01-01T00:00:00Z